NCT04517747View on ClinicalTrials.gov

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

January 13, 2022

Study Completion Date

January 20, 2023

Conditions

Gastric AdenocarcinomaMetastatic Adenocarcinoma of the Gastroesophageal Junction

Interventions

DRUG

Ramucirumab

chemotherapy i.v.

DRUG

TAS 102

p.o. twice daily

Trial Locations (5)

20246

Hamburg Hämatologisch-Onkologische Praxis Eppendorf-Facharztzentrum Eppendorf, Hamburg

60488

Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt

68167

Tagestherapiezentrum am ITM Universitätsmedizin Mannheim, Mannheim

81675

Technische Universität München Klinikum Rechts der Isar, München

89081

Universitätsklinikum Ulm, Ulm

All Listed Sponsors

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT04517747 - Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction | Biotech Hunter | Biotech Hunter